Start-up  Early Stage CEO Forum

Biotech Start-up / Early Stage CEO Forum - 2020 Programme

The prevailing theme during this CEO Forum is survivability and thrivability during COVID-19.

A unique, powerful and valuable space for the candid sharing of experience between 25 of the sector’s emerging and innovative pre-series A Biotech executives. Like-minded Executives are joined by 2 appropriate and value-matched industry stakeholders and partners to provide expertise, experience and best practice on strategic areas of focus. Case studies will also be delivered by a number of executives in the room who have enjoyed success or navigated key challenges in their pursuit of company growth.

A pre-registration only, exclusive hollow square forum where all participants are active discussants. This CEO forum is delivered in a virtual setting via Zoom.

Attendance is FREE, however executives must satisfy a number of key criteria points outlined during registration.


Qualifier: Company executives must be pre-series A and from a US-based therapeutic-indication Biotech company

Date: Wednesday, 7th October 2020

Timings: 11:00AM - 1:00PM EDT / 08:00AM - 10.00AM PDT


Co-Hosted by:

Premier Research   Goodwin Procter


Moderator – Sarah Solomon, Partner, Technology & Life Sciences Group, Goodwin Procter

Solomon_Sarah_LGoodwin 300x150

Ms. Solomon represents biotechnology, pharmaceutical, medical device and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as joint research and development agreements, co-commercialization agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, supply, distribution, clinical trial, university and academic licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and structured M&A transactions). Ms. Solomon also counsels clients in connection with international transactions in North America, South America, Europe and Asia.


11.00 – Realizing the value of a therapeutic asset

  • Early front-end decisions
    • Project Objectives (notes: the talking points would be: Research stage target product profiles, competition assessments, differentiation, etc.)
    • Optimal trial designs
    • Regulatory strategies
  • Efficiency in trial initiation
    • Site selection strategies
    • Approaches to initiating trials
  • Managing decision points
    • Inflection points and their impact
  • What is success?
Sameena Sharif, PhD, Senior Vice President, Product Strategy, Premier Research
Abie Ekangaki, PhD, Vice President, Statistical Consulting, Premier Research
Nach Davé, RPh. MSc, Vice President, Development Strategy, Premier Research

Sameena Sharif  AE  ND          Premier Research 300x150 


11.20 – CEO Case Study - Company creation, ideation, a $33m Series A finance raising and collaboration during COVID-19 

Shawn Leland, Founder and Chief Business Officer, Elevation Oncology

Shawn Leland      elevation-oncology-logo

Shawn M. Leland is the Founder of Elevation Oncology and currently serves as its Chief Business Officer overseeing all day-to-day operations.  Shawn brings over a decade of experience in medical affairs and business development for the pharmaceutical/biotech industry, with a focus on building collaborations to realize the full potential of targeted and personalized therapeutics. Shawn has been involved in global transactions totaling more than $450 million in upfront payments and milestone payments at Eli Lilly, ARIAD Pharmaceuticals, Argos Therapeutics and Verastem Oncology.  Shawn has also served as an expert strategic consultant for Catenion providing guidance on portfolio management for pharmaceutical/biotech companies.


11.40 – Making the most of your FDA Interactions to aid preclinical or other preparatory studies / initial clinical development strategies

Alex Varond, Partner, Technology and Life Sciences Group, Goodwin Procter

Varond_AlexanderGoodwin 300x150

12.00 – CEO Case Study - Preclinical stage partnering rationale, strategies and structures 

  • The rationale for partnering preclinical stage compounds, examples of preclinical stage deal strategies and structures, payment strategies, terms and KSFs.
Dr Joseph Reddy, President and CEO, Lacerta Therapeutics

joe-reddy      lacerta-therapeutics-logo-shadow

Dr. Reddy has over 15 years of progressive leadership in life science research, business management and product development. He has led biotech start-ups in agricultural biotechnology, therapeutics and medical devices, across the R&D-commercial continuum. As an Entrepreneur in Residence at the Florida Institute for Commercialization of Public Research, he has worked with numerous start-up companies as an advisor, provided interim management support and served on their Boards to ensure successful commercialization of technology licensed from public research institutions in Florida. Previously, he was the Director of Program Management at Nanotherapeutics, Inc., where he has managed several multi-million-dollar NIH/BARDA grants and contracts. He received his Ph.D. from the University of Idaho and his M.B.A. from the University of Florida.


12.20 – General Discussion 

Discussion to include but not limited to:

  • Selecting the right clinical model for your business
  • Attracting the right investor and level of investment
  • Overcoming challenges in securing a substantial Series A
  • Early-stage partnerships to grow your business

Moderator – Sarah Solomon, Partner, Technology & Life Sciences Group, Goodwin Procter

Solomon_Sarah_LGoodwin 300x150

Ms. Solomon represents biotechnology, pharmaceutical, medical device and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as joint research and development agreements, co-commercialization agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, supply, distribution, clinical trial, university and academic licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and structured M&A transactions). Ms. Solomon also counsels clients in connection with international transactions in North America, South America, Europe and Asia.


13.00 – Forum Close

 

Current CEO participants include:

Alloplex ALtrix AmideBIo ariz_logo
BYO Cyclone Deciduous Deck
eikonoklastes_Logo_Full_Color Elex Evolve Felix Biotechnology
General Probiotics Igia Immix ImmunoOncholytics LLC-1
iSTAT-Therapeutics-Inc. Lactocore NeuroTrauma Oncospherix
Phileas Pharma-1 Phyteau-1 RetroTherapy Inc. SciBac
Sigilon-Brand-GrayLogoTM-WhiteBG-100319 SimplSeq, Inc. Somagevity Inc. Sunshine Bio Inc.
vida-big Vincere Biosciences-1 Wildflower Biopharma  

 

For enquiries contact:

Matt Pullan, SVP, Business Development
matt@lsxleaders.com 

REGISTER NOW